Imatinib drugs, treatment of basal cell carcinoma Vismodegib
Vismodegib(tradenameErivedge)isadrugforthetreatmentofbasal-cellcarcinoma(BCC).TheapprovalofvismodegibonJanuary30,2012,representsthefirst
Vismodegib (trade name Erivedge) is a drug for the treatment of basal-cell carcinoma (BCC). The approval of vismodegib on January 30, 2012, represents the first Hedgehog signaling pathway targeting agent to gain U.S. Food and Drug Administration (FDA) approval.[1] The drug is also undergoing clinical trials for metastatic colorectal cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, medulloblastomachondrosarcoma as of June 2011.[2] The drug was developed by the biotechnology / pharmaceutical company
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View